Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

ProMIS Neurosciences Q3 EPS $(0.85) Down From $(0.20) YoY

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.
byBenzinga Newsdesk
November 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Lynparza in Combination with Abiraterone Granted Priority Review in the US for Patients with Metastatic Castration-resistant Prostate Cancer

By Charles Gross
Today, 1:53 PM
AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.

AZN